Cited by 2,825Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsLung Cancer Research Studies

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Open access

Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen R., Brahmer, Julie R., Swanson, Scott J., Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Liberman, Moishe, Vokes, Everett E., Taube, Janis M., Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y., Girard, Nicolas·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2202170PMC PMC9844511

Open this paper in CoChat — free account

Abstract

BACKGROUND: Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however, data from phase 3 trials are needed to confirm these findings. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IB to IIIA resectable NSCLC to receive nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone, followed by resection. The primary end points were event-free survival and pathological complete response (0% viable tumor in resected lung and lymph nodes), both evaluated by blinded independent review. Overall survival was a key secondary end point. Safety was assessed in all treated patients. RESULTS: The median event-free survival was 31.6 months (95% confidence interval [CI], 30.2 to not reached) with nivolumab plus chemotherapy and 20.8 months (95% CI, 14.0 to 26.7) with chemotherapy alone (hazard ratio for disease progression, disease recurrence, or death, 0.63; 97.38% CI, 0.43 to 0.91; P = 0.005). The percentage of patients with a pathological complete response was 24.0% (95% CI, 18.0 to 31.0) and 2.2% (95% CI, 0.6 to 5.6), respectively (odds ratio, 13.94; 99% CI, 3.49 to 55.75; P<0.001). Results for event-free survival and pathological complete response across most subgroups favored nivolumab plus chemotherapy over chemotherapy alone. At the first prespecified interim analysis, the hazard ratio for death was 0.57 (99.67% CI, 0.30 to 1.07) and did not meet the criterion for significance. Of the patients who underwent randomization, 83.2% of those in the nivolumab-plus-chemotherapy group and 75.4% of those in the chemotherapy-alone group underwent surgery. Grade 3 or 4 treatment-related adverse events occurred in 33.5% of the patients in the nivolumab-plus-chemotherapy group and in 36.9% of those in the chemotherapy-alone group. CONCLUSIONS: In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone. The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2202170

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The National Comprehensive Cancer Network
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citation
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L. L. C., Tsuboi, M., He, J., John, T., Grohé, C., Majem, M., Goldman, J. W., Лактионов, К. К., Kim, S., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,849
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Felip, E., Altorki, N. K., Zhou, C., Csőszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A. V., Akopov, A. L., Martínez‐Martí, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,497
Self-citation
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Self-citation
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Self-citation
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Self-citation

Flagged first, then by citations

Show all 38 references

Sorted by citations

Items 701–800 of 1,000

Immunotherapy for Early-Stage Non–Small Cell Lung Cancer: A Practical Guide of Current Controversies
Phillips, W. J., Jackson, A., Kidane, B., Lim, G., Navani, V., & Wheatley‐Price, P. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.01.006 · Cited by 12
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients
Greib, A., Zhao, S., Ploch, M., Henricks, J., Easterling, R. S., Moodabagil, M., Lopez, G., Li, M., Goodyear, E. G., Sharp, J., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2469375 · Cited by 10
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”
Delcuratolo, M. D., Crespi, V., Saba, G., Mogavero, A., Napoli, V. M., Garbo, E., Cani, M., Ungaro, A., Reale, M. L., Merlini, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102918 · Cited by 10
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
Marron, T. U., Luke, J. J., Hoffner, B., Perlmutter, J., Szczepanek, C. M., Anagnostou, V., Silk, A. W., Romero, P. J., Garrett-Mayer, E. S., & Emens, L. A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010760 · Cited by 12
Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-small Cell Lung Cancer
Chen, J., Zhao, Z.-R., Deng, H., Yang, C., Mo, Z., Fan, L., He, J., & Li, S. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.03.033 · Cited by 10
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee
Jones, S. B., Chan, C., Filippi, A. R., Harada, K., Louie, A. V., Lindsay, C. R., Nadal, E., Schuffenegger, P. M., Woolf, D., & Finn, C. F. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.004 · Cited by 10
The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer
Chandra, R., Ehab, J., Hauptmann, E., Gunturu, N. S., Karalis, J. D., Kent, D. O., Heid, C. A., Reznik, S. I., Sarkaria, I. S., Huang, H., et al. (2025) · Cancers · doi:10.3390/cancers17111732 · Cited by 11
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
Xenophontos, E., Levra, N. G., Durieux, V., van Geffen, W. H., Grisay, G., Alonso, C. D. L. P., Arasanz, H., Prisciandaro, E., Ferrara, R., Derks, J. L., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108671 · Cited by 10
Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-Immunotherapy
Ohara, S., Suda, K., & Tsutani, Y. (2025) · Cells · doi:10.3390/cells14171312 · Cited by 10
Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017–2025
Evison, M., Ahmed, T., Chitnis, M. M., Ward, R., Netto, D., Cove-Smith, L., Shah, R. N. H., Steele, N. L., Walls, G., West, D., et al. (2025) · Thorax · doi:10.1136/thorax-2025-223096 · Cited by 10
CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients
Lin, H., Han, Y., Guo, L., Liu, C., Li, H., Li, J., Wang, C., Zhou, L., Zhang, X., Sun, L., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02435-0 · Cited by 10
Self-citation
Correlation between PD-L1 expression and radiomic features in early-stage lung adenocarcinomas manifesting as ground-glass nodules
Shi, W., Yang, Z., Zhu, M., Zou, C., Li, J., Liang, Z., Wang, M., Yu, H., Yang, B., Wang, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.986579 · Cited by 10
miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01394-1 · Cited by 12
The unfolding story of dying tumor cells during cancer treatment
He, S., Huang, Q., & Cheng, J. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1073561 · Cited by 10
Robotic bronchoscopy: potential in diagnosing and treating lung cancer
Duke, J. D., & Reisenauer, J. S. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2192929 · Cited by 10
Enhanced recovery of postoperative nursing for single-port thoracoscopic surgery in lung cancer patients
Hu, X., & He, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1163338 · Cited by 10
Does the number of cycles of neoadjuvant therapy affect the efficacy of neoadjuvant chemoimmunotherapy for non‐small cell lung cancer in locally advanced stage? Retrospective experience based on a single center
Zhu, D., Huang, Z., Xiao, K., Bian, D., Zhang, J., Zhang, Z., Zhu, S., Yin, L., Zhu, J., & Zhang, P. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13971 · Cited by 10
Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the “PACIFIC” Era
Adachi, H., Ito, H., Isaka, T., Murakami, K., Miura, J., Kikunishi, N., Shigeta, N., Saito, H., Yoshida, D., Yokose, T., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.07.004 · Cited by 10
Self-citation
Brief Report: Acetaminophen Reduces Neoadjuvant Chemoimmunotherapy Efficacy in Patients With NSCLC by Promoting Neutrophil Extracellular Trap Formation: Analysis From a Phase 2 Clinical Trial
Li, C., Wu, J., Zhang, L., Wang, F., Xu, L., Zhao, Y., Xiao, Y., Zhuang, F., Hou, L., Zhao, D., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100556 · Cited by 10
Transformation of Lung Squamous Cell Carcinoma to Small Cell Lung Cancer After Immunotherapy Resistance: A Case Report
Wang, D., Ye, W., Chen, D., Shi, Q., & Ma, D. (2023) · Cancer Management and Research · doi:10.2147/cmar.s420485 · Cited by 10
Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process
Tankel, J., Spicer, J. D., Chu, Q. S.-C., Fiset, P., Kidane, B., Leighl, N. B., Joubert, P., Maziak, D. E., Palma, D. A., McGuire, A., et al. (2023) · Current Oncology · doi:10.3390/curroncol30120755 · Cited by 10
Self-citation
Computational markers for personalized prediction of outcomes in non-small cell lung cancer patients with brain metastases
Benzekry, S., Schlicke, P., Mogenet, A., Greillier, L., Tomasini, P., & Simon, E. (2023) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10245-3 · Cited by 11
Development, Characterization, and Radiation Dosimetry Studies of 18F-BMS-986229, a 18F-Labeled PD-L1 Macrocyclic Peptide PET Tracer
Kim, J., Donnelly, D. J., Tran, T., Pena, A., Shorts, A. O., Petrone, T. V., Zhang, Y., Boy, K. M., Scola, P. M., Tenney, D. J., et al. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01889-4 · Cited by 10
Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis
Wang, H., Liang, S., Yu, Y., & Han, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1276549 · Cited by 10
Adaptive Control of Tumor Growth
Derbal, Y. (2024) · Cancer Control · doi:10.1177/10732748241230869 · Cited by 10
Defining resectability: When do you try to take it out?
Etienne, H., Battilana, B., Spicer, J. D., Werner, R. S., & Opitz, I. (2024) · JTCVS Open · doi:10.1016/j.xjon.2024.03.012 · Cited by 10
Self-citation
Top advances of the year: Perioperative therapy for lung cancer
Aredo, J. V., & Wakelee, H. A. (2024) · Cancer · doi:10.1002/cncr.35357 · Cited by 10
Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy
Shan, J., Liu, Z., Chen, S., Du, C., Li, B., Ruan, L.-X., Kong, M., Wang, L., Du, M., Shi, S., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03462-4 · Cited by 10
Long-term clinical outcomes and prognostic factors of upfront surgery as a first-line therapy in biopsy-proven clinical N2 non-small cell lung cancer
Bertolaccini, L., Prisciandaro, E., Guarize, J., Girelli, L., Sedda, G., Filippi, N., de Marinis, F., & Spaggiari, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933278 · Cited by 10
Pathological Complete Response to Neoadjuvant Chemoimmunotherapy Correlates with Peripheral Blood Immune Cell Subsets and Metastatic Status of Mediastinal Lymph Nodes (N2 Lymph Nodes) in Non-Small Cell Lung Cancer
Ma, T., Wen, T., Xu, C., Wang, Y., Wei, P., Yang, B., Yi, L., Wang, X., Yan, Z., Wang, J., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.002 · Cited by 10
Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer
Rolfo, C. D., & Russo, A. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.010 · Cited by 10
Perioperative Immunotherapy in Non-Small Cell Lung Cancer
O'Brien, J. A., & Bodor, J. N. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01160-6 · Cited by 9
Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy
Berezowska, S., Keyter, M., Bouchaab, H., & Weissferdt, A. (2024) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000441 · Cited by 10
Early Detection and Interception of Lung Cancer
Chang, A. E. B., Potter, A. L., Yang, C. J., & Sequist, L. V. D. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.004 · Cited by 9
Summary of the best evidence for prehabilitation management of patients with non-small cell lung cancer
Wu, W., Li, H., & Fan, R. (2024) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2024.100516 · Cited by 9
“Percentage” and “size” of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy
Sun, W., Qu, L., Wu, J., Liu, X., Wang, C., Jiang, Y., Liu, Y., Chen, M., Wang, X., & Lin, D. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.05.009 · Cited by 9
Self-citation
Induction Immunochemotherapy Yields a Higher Conversion Rate and Better Overall Survival than Chemotherapy in Initially Unresectable Esophageal Squamous Cell Carcinoma
Huang, S., Wang, S., Gao, Z., Li, Z., Wu, H., Xu, W., Tang, Y., He, Z., Fu, J., & Qiao, G. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15458-8 · Cited by 9
Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review
Kaira, K., Ichiki, Y., Imai, H., Kawasaki, T., Hashimoto, K., Kuji, I., & Kagamu, H. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-142 · Cited by 9
Pulmonologists’ Attitudes and Role in Precision Medicine Biomarker Testing for Non-Small Cell Lung Cancer
Fox, A. H., Rudzinski, M. A., Nietert, P. J., & Silvestri, G. A. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.06.001 · Cited by 9
Correlation of K trans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy
Wang, D., Liu, S.-R., Fu, J., Zhang, P., Zheng, S., Qiu, B., Liu, H., Ye, Y., Guo, J., Zhou, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008574 · Cited by 9
Prehabilitation for Older Adults Undergoing Lung Cancer Surgery: A Literature Review and Needs Assessment
Zhao, J. Y., Presley, C. J., Madariaga, M. L. L., Ferguson, M. K., Merritt, R. E., & Kneuertz, P. J. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.07.004 · Cited by 9
Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer
Zhu, S., Wu, R., Liu, X., Xie, B., Xie, C., Li, S., Wu, Z., Zhang, Z., Tang, Z., & Gu, L. (2024) · Future Oncology · doi:10.1080/14796694.2024.2376513 · Cited by 9
CD8+ T cells infiltrating into tumors were controlled by immune status of pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC) patients’ prognosis treated with chemoimmunotherapy
Bai, Z., Cheng, X., Ma, T., Li, G., Wang, X., Wang, Z., Yi, L., & Liu, Z. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107991 · Cited by 9
Concordance of Whole-Slide Imaging and Conventional Light Microscopy for Assessment of Pathologic Response Following Neoadjuvant Therapy for Lung Cancer
Deutsch, J. S., Wang, D., Chen, K. Y., Cimino‐Mathews, A., Thompson, E. D., Jedrych, J. J., Anders, R. A., Gabrielson, E., Illei, P. B., Uttam, S., et al. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102166 · Cited by 9
Self-citation
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
Zhou, N., Leung, C. H., William, W. N., Weissferdt, A., Pataer, A., Godoy, M. C. B., Carter, B. W., Fossella, F. V., Tsao, A. S., Blumenschein, G. R., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009677 · Cited by 9
Combination Immunotherapy With Radiotherapy in Non‐Small Cell Lung Cancer: A Review of Evidence
Burr, J., Johnson, K. C., Carmicheal, J., Lin, C. H., & Ganti, A. K. (2024) · Cancer Medicine · doi:10.1002/cam4.70402 · Cited by 9
Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory Study
Ohara, S., Suda, K., Sudhaman, S., Hamada, A., Chiba, M., Shimoji, M., Takemoto, T., Kalashnikova, E. V., Cheung, S. K., Krainock, M. R., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100762 · Cited by 9
Self-citation
Perioperative Treatment in Gastric Cancer: A Fast-Changing Field
Costa, M., Fernandes, C. L., & Magalhães, H. (2024) · Cancers · doi:10.3390/cancers16234036 · Cited by 9
Next-generation immunotherapy: igniting new hope for lung cancer
Li, M. S. C., Chan, A. L. S., Mok, K. K. S., Chan, L. L., & Mok, T. S. K. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241302021 · Cited by 9
Neoadjuvant immunotherapy for non-small cell lung cancer: Opportunities and challenges
Hu, J., Zhang, J., Wan, S., & Zhang, P. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.11.003 · Cited by 9
Identification of ALDH7A1 as a DNA-methylation-driven gene in lung squamous cell carcinoma
Liang, G., He, J., Chen, T., Zhang, L., Yu, K.-Z., & Shen, W. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2442529 · Cited by 9
Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non–Small Cell Lung Cancer
Schüler, M. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1441 · Cited by 9
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
Zeng, L., Yan, H., Jiang, W., Qin, H., Dai, J., Zhang, Y., Wei, S. N., Chen, S., Liu, L., Xiong, Y., et al. (2025) · Med · doi:10.1016/j.medj.2025.100574 · Cited by 9
Efficacy and safety of induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced non-small cell lung cancer: A retrospective study
Liu, L., Gao, C., Yang, Y., Tang, M., Zhao, T., Chen, D., Jin, J., Xu, Y., Li, G., & Zhong, Q. (2025) · Radiation Oncology · doi:10.1186/s13014-025-02616-9 · Cited by 9
Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives
Jin, X., Zhao, W., Li, G., & Jiang, J. (2025) · Cancer Control · doi:10.1177/10732748251334434 · Cited by 9
A METTL3-NFE2L3 axis mediates tumor stemness and progression in lung adenocarcinoma
Zhao, Y., Zhang, L., Xia, L., Haoran, E., Wang, T., Lu, H., Chen, H., She, Y., Tang, H., Wu, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt7682 · Cited by 9
Targeting the nuclear orphan receptor NR4A1: a key target in lung cancer progression and therapeutic resistance
Jin, M., Wang, Y., Song, M., Guo, W., Li, S., & Pu, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1566598 · Cited by 9
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers
Ni, J., Li, C., Xu, X., Xu, Q., Yin, Q., Chen, H., Zhou, S., Li, J., Zheng, Q., Xie, Y., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04263-z · Cited by 9
Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival
Cooper, A. J., Garbo, E., Arfè, A., Conroy, M. R., Shaverdian, N., Bott, M. J., Gorría, T., Pecci, F., Aldea, M. D., Anagnostou, V., et al. (2025) · Cancer · doi:10.1002/cncr.70081 · Cited by 9
Self-citation
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial
Qiu, B., Zhao, Y., He, W., Zeng, W., Zhang, H., Feng, W., Jia, J., Wang, D., Wang, D., Liu, F., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02408-3 · Cited by 9
Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancer
Matsumoto, K., Noda, Y., Hachiya, K., Muramatsu, F., Okamoto, N., Jia, W., Shiroyama, T., Mori, M., Tamiya, M., Kinehara, Y., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-025-04161-7 · Cited by 9
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer
Wang, Y., Xiang, Y., Chen, X.-W., Zhang, T., Wang, J.-Y., Liu, W.-Y., Deng, L., Wang, L.-H., Gao, S., & Bi, N. (2026) · Military Medical Research · doi:10.1186/s40779-025-00679-z · Cited by 9
Lung Cancer in Never-Smokers: Risk Factors, Driver Mutations, and Therapeutic Advances
Chen, P.-M., Huang, Y., & Li, C.-Y. (2026) · Diagnostics · doi:10.3390/diagnostics16020245 · Cited by 9
Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer
Baratz, H. Q., Hidalgo, C. M., Price, D. L., Abel, K. M. V., Lester, S. C., Routman, D. M., Wilson, J., Baral, B., Bayne, H. E. F., McGarrah, P. W., et al. (2026) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2026.0080 · Cited by 9
Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges
Okuyama, K., Naruse, T., Matsushita, Y., Fujimoto, J., Yanamoto, S., Lei, Y. L., & Hu, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02609-6 · Cited by 9
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
Chaft, J. E., Sun, Z., Rudin, C. M., Khullar, O. V., Simone, C. B., Oettel, K. R., Kozono, D., Sunkara, R., Faller, B. A., Isbell, J. M., et al. (2026) · JAMA · doi:10.1001/jama.2026.8992 · Cited by 9
Self-citation
The Value of Radiotherapy in Patients With Resectable Stage IIIA Non–Small-Cell Lung Cancer in the Era of Individualized Treatment: A Population-Based Analysis
Liu, B., Wang, Z., Zhao, H., Gao, S., Wang, H., Zhang, Y., Fan, K., Tao, R., Li, Y., Feng, J., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.09.011 · Cited by 9
Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non–small cell lung cancer
Lengel, H. B., Zheng, J., Tan, K. S., Liu, C. C., Park, B. J., Rocco, G., Adusumilli, P. S., Molena, D., Yu, H. A., Riely, G. J., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.10.056 · Cited by 9
High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy
Jia, W., Guo, H., Wang, M., Li, J., Yu, J., Zhu, H., & Wu, G. (2023) · MedComm · doi:10.1002/mco2.213 · Cited by 9
Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
Zhou, N. Q., Chen, Y., Huang, Q., Jiang, L., Liao, H., Gou, H., Lü, Y., Che, G., & Zhang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111325 · Cited by 10
Ten-Year Outcome and Development of Virtual-Assisted Lung Mapping in Thoracic Surgery
Nagano, M., & Sato, M. (2023) · Cancers · doi:10.3390/cancers15071971 · Cited by 9
Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker
Khan, S. R., Scheffler, M., Soomar, S. M., Rashid, Y. A., Moosajee, M., Ahmad, A., Raza, A., & Shahab Uddin, M. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154455 · Cited by 9
Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity
Gong, Y., Pang, H., Yu, Z., Wang, X., Li, P., & Zhang, Q. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2200034 · Cited by 9
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
Borm, F. J., Smit, J. N., Bakker, J., Wondergem, M., Smit, E. F., de Langen, A. J., & de Gruijl, T. D. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2204745 · Cited by 9
Neoadjuvant immunotherapy in patients with pulmonary lymphoepithelioma-like carcinoma
Hong, H.-Z., Li, J., Zhang, J., Li, H., Peng, L., Wu, Y.-L. L. C., & Zhong, W. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107220 · Cited by 9
Efficacy of Preoperative Biopsy in Predicting the Newly Proposed Histologic Grade of Resected Lung Adenocarcinoma
Ohtani-Kim, S. J.-Y., Taki, T., Tane, K., Miyoshi, T., Samejima, J., Aokage, K., Nagasaki, Y., Kojima, M., Sakashita, S., Watanabe, R., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100209 · Cited by 9
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study
Wang, X., Huang, J., Huang, H., Liu, Y., Ji, C., & Liu, J. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01379-y · Cited by 9
Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications
CAMILLI, A. D., & Fischer, G. W. (2023) · Current Oncology · doi:10.3390/curroncol30080554 · Cited by 9
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Yu, S., Zhai, S., Gong, Q., Xiang, C., Gong, J., Wu, L., & Pu, X. (2023) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001046 · Cited by 9
Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
Schütte, W., Gutz, S., Nehls, W., Blum, T. G., Brückl, W. M., Buttmann‐Schweiger, N., Büttner, R., Christopoulos, P., Delis, S., Deppermann, K.-M., et al. (2023) · Pneumologie · doi:10.1055/a-2029-0134 · Cited by 11
Harnessing G-quadruplex ligands for lung cancer treatment: A comprehensive overview
Figueiredo, J., Djavaheri‐Mergny, M., Ferret, L., Mergny, J., & Cruz, C. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103808 · Cited by 9
A Nanodrug-Enabled chemosensitization of cancer stem cells against tumor progression and metastasis
Wang, W., Zhang, D., Jiang, Z., Zhang, X., Jiang, Y., & Luan, Y. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.147121 · Cited by 9
Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science
Chan, L. L., Kung, J. W. C., & Chan, S. L. (2023) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.08.001 · Cited by 9
Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
Zhao, J., Hao, S., Li, Y., Liu, X., Liu, Z., Zheng, C., & Han, D. (2023) · ImmunoTargets and Therapy · doi:10.2147/itt.s437911 · Cited by 9
Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer
Böttger, F., Radonic, T., Bahce, I., Monkhorst, K., Piersma, S. R., Pham, T. V., Dingemans, A. C., Hillen, L. M., Santarpía, M., Giovannetti, E., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13555 · Cited by 9
Event-free survival as a predictor of overall survival and recurrence burden of patients with non–small cell lung cancer receiving neoadjuvant therapy
Donington, J. S., Hu, X., Zhang, S., Song, Y., Arunachalam, A., Chirovsky, D. R., Gao, C., Lerner, A., Jiang, A., Signorovitch, J., et al. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.12.006 · Cited by 9
Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis
Mei, T., Zhou, Q., & Gong, Y. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.12.006 · Cited by 9
The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
Güven, D. C., Şahin, T. K., & Kılıçkap, S. (2023) · Cancers · doi:10.3390/cancers16010156 · Cited by 9
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent
Strohbehn, G. W., & Gyawali, B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00857-9 · Cited by 9
Safety and feasibility of minimally invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer: a propensity score-matched analysis in China
Cui, H., Liang, W., Cui, J., Song, L., Yuan, Z., Chen, L., & Wei, B. (2023) · Gastroenterology report · doi:10.1093/gastro/goae005 · Cited by 9
Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB–IIIB lung squamous cell carcinoma
Liu, J.-C., Zhu, L., Tang, M., Huang, X., Gu, C., He, C., Lv, X., & Hu, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-54371-8 · Cited by 10
Advances in lung cancer surgery: the role of segmentectomy in early–stage management
Bertolaccini, L., Casiraghi, M., Uslenghi, C., Diotti, C., Mazzella, A., Caffarena, G., & Spaggiari, L. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2324083 · Cited by 9
Deep Learning Based on Computed Tomography Predicts Response to Chemoimmunotherapy in Lung Squamous Cell Carcinoma
Peng, J., Xie, B., Ma, H., Wang, R., Hu, X., & Huang, Z. (2024) · Aging and Disease · doi:10.14336/ad.2024.0169 · Cited by 9
Surgically resectable nonsmall cell lung cancer: a contemporary approach
D'Amours, M.-F., Wu, F. T. H., Theisen-Lauk, O., Chan, E. K., McGuire, A., & Ho, C. (2024) · European Respiratory Journal · doi:10.1183/13993003.00332-2024 · Cited by 9
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
Provencio, M., de Lope, L. R., Serna‐Blasco, R., Nadal, E., Taín, P. D., Massutí, B., González-Larriba, J. L., Insa, A., Sánchez-Hernández, A., Casal‐Rubio, J., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107865 · Cited by 9
Self-citation
Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A retrospective study
He, J., Luo, G., Liu, S., Chen, L., Chen, Z., Zhang, B., Lin, J., Qin, W., Li, H., Zhou, H., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102058 · Cited by 9
Natural Killer Cell-Secreted IFN-γ and TNF-α Mediated Differentiation in Lung Stem-like Tumors, Leading to the Susceptibility of the Tumors to Chemotherapeutic Drugs
Kaur, K., Celis, A. S., & Jewett, A. (2025) · Cells · doi:10.3390/cells14020090 · Cited by 9
Automatic machine learning accurately predicts the efficacy of immunotherapy for patients with inoperable advanced non-small cell lung cancer using a computed tomography-based radiomics model
Lin, S., Ma, Z., Yao, Y., Huang, H., Chen, W., Tang, D., & Gao, W. (2025) · Diagnostic and Interventional Radiology · doi:10.4274/dir.2024.242972 · Cited by 9
Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer
Eklund, E. Ä., Svensson, J. B., Näslund, L. S., Yhr, M., Sayin, S. I., Wiel, C., Akyürek, L. M., Torstensson, P., Sayin, V. I., Hallqvist, A., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03342-6 · Cited by 9
Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study
Zhao, D., Xu, L., Wu, J., She, Y., Su, H., Hou, L., Haoran, E., Zhang, L., Grossi, F., Subramanian, M. P., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-476 · Cited by 9

Authors: Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., Kerr, K., Wang, C., Ciuleanu, T.-E., Saylors, G. B., Tanaka, F., Ito, H., Chen, K.-N., Liberman, M., Vokes, E. E., Taube, J. M., Dorange, C., Cai, J., Fiore, J., Jarkowski, A., Balli, D., Sausen, M., Pandya, D., Calvet, C. Y., & Girard, N.
Affiliations: Johns Hopkins University (US)
From the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore (P.M.F., S.R.B., J.R.B., J.M.T.); McGill University Health Center (J.S.), and Centre Hospitalier de l’Université de Montréal (M.L.) — both in Montreal; Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai (S.L.), Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin (C.W.), and Peking University School of Oncology, Beijing Cancer Hospital, Beijing (K.-N.C.) — all in China; Hospital Universitario Puerta de Hierro, Madrid (M.P.); Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama (T.M.), the University of Occupational and Environmental Health, Kitakyushu (F.T.), and Kanagawa Cancer Center, Yokohama (H.I.) — all in Japan; Dana–Farber Cancer Institute, Boston (M.M.A., S.J.S.); Vall d’Hebron Institute of Oncology, Barcelona (E.F.); Aberdeen Royal Infirmary, Aberdeen, United Kingdom (K.K.); Institutul Oncologic Prof. Dr....
ORCID: Forde, Patrick M.
Felip, Enriqueta
Calvet, Christophe Y.
Girard, Nicolas
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-05-26
Volume: 386
Issue: 21
Pages: 1973-1985
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2202170
PMC: PMC9844511
OpenAlex: W4223502512
Cited by: 2,825
References: 38
Citations by year: 2026: 583 · 2025: 683 · 2024: 724 · 2023: 624 · 2022: 209
FWCI: 361.74
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Bristol-Myers Squibb (N/A)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: nivolumab, neoadjuvant therapy, non-small cell lung cancer, resectable lung cancer, platinum-based chemotherapy, immune checkpoint inhibitors, event-free survival, pathological complete response, overall survival, treatment-related adverse events
MeSH terms: Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, Platinum Compounds, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks